As such, it represents a promising individualized and targeted therapeutic strategy for HCC tumors with high TFRC-expression, but also underscores the utility of the readily modifiable NV platform – a modality which could easily be deployed to other cancer types (such as lung cancer and kidney cancer) by modifying these tumor-specific targeting molecules. The gene discussed is TFRC; the disease is cancer.